Top

Published in:

01-09-2007 | Original Article

A pravastatin dose-escalation study in systemic lupus erythematosus

Authors: Karen H. Costenbader, Matthew H. Liang, Lori B. Chibnik, Juliet Aizer, Hannah Kwon, Victoria Gall, Elizabeth W. Karlson

Published in: Rheumatology International | Issue 11/2007

Abstract

Statin medications have been suggested for widespread use in patients with systemic lupus erythematosus (SLE). We studied the dose effectiveness and tolerability of pravastatin in SLE. We compared 41 SLE subjects in a two-month open-label dose-titration study of pravastatin to 22 SLE controls. Lipids, ALT, CPK, CRP, adverse effects were assessed. Linear mixed models assessed changes in lipids and CRP, comparing pravastatin subjects to controls. After 1 month of pravastatin 10 mg a day, total cholesterol decreased by 16% (±12.1%) and LDL by 24% (±17%), compared with 1.8% (±7.5%) and 2.6% (±8.6%) decreases in controls (P < 0.001). CRP did not decline. Glucocorticoids appeared to decrease pravastatin effectiveness. Serum CPK increased in one subject. Pravastatin reduced LDL and total cholesterol levels approximately the same degree observed in normal individuals, but the effect appeared blunted in those on modest doses of glucocorticoids and those with higher BMI.

Jonsson H, Nived O, Sturfelt G (1989) Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine (Baltimore) 68(3):141–150

Abu-Shakra M, Urowitz MB, Gladman DD et al (1995) Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol 22(7):1259–1264PubMed

Ward M (1999) Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 42:338–346PubMedCrossRef

Manzi S, Meilahn EN, Rairie JE et al (1997) Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol (145):408–415PubMed

Petri M, Perez-Gutthann S, Spence D et al (1992) Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 93(5):513–519PubMedCrossRef

Rahman P, Urowitz MB, Gladman DD et al (1999) Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus. J Rheumatol 26(11):2363–2368PubMed

Esdaile JM, Abrahamowicz M, Grodzicky T et al (2001) Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 44(10):2331–2337PubMedCrossRef

Roman MJ, Salmon JE, Sobel R et al (2001) Prevalence and relation to risk factors of carotid atherosclerosis and left ventricular hypertrophy in systemic lupus erythematosus and antiphospholipid antibody syndrome. Am J Cardiol 87(5):663–666 (A11)

Asanuma Y, Oeser A, Shintani AK et al (2003) Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 349(25):2407–2415PubMedCrossRef

10.

Roman MJ, Shanker BA, Davis A et al (2003) Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 349(25):2399–2406PubMedCrossRef

11.

ALLHAT-LLT (2002) Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT) Jama 288(23):2998–3007CrossRef

12.

Shepherd J, Cobbe SM, Ford I et al (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333(20):1301–1307PubMedCrossRef

13.

Simes J, Furberg CD, Braunwald E et al (2002) Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project. Eur Heart J 23(3):207–215PubMedCrossRef

14.

White HD, Simes RJ, Anderson NE et al (2000) Pravastatin therapy and the risk of stroke. N Engl J Med 343(5):317–326PubMedCrossRef

15.

Nissen SE, Nicholls SJ, Sipahi I et al (2006) Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. Jama 295(13):1556–1565PubMedCrossRef

16.

Masumoto A, Hirooka Y, Hironaga K et al (2001) Effect of pravastatin on endothelial function in patients with coronary artery disease (cholesterol-independent effect of pravastatin). Am J Cardiol 88(11):1291–1294PubMedCrossRef

17.

Mason JC, Ahmed Z, Mankoff R et al (2002) Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury. Circ Res 91(8):696–703PubMedCrossRef

18.

Lieberman EH, Gerhard MD, Uehata A et al (1996) Flow-induced vasodilation of the human brachial artery is impaired in patients <40 years of age with coronary artery disease. Am J Cardiol 78(11):1210–1214PubMedCrossRef

19.

Giri S, Parke AL, Waters DD (1998) Controlling cardiovascular risk factors in systemic lupus erythematosus. J Musculoskel Med 15:42–52

20.

Aranow C, Ginzler EM (2000) Coronary artery disease in SLE: high suspicion leads to early recognition. J Musculoskel Med 17:473–482

21.

Urowitz MB, Gladman DD (2000) How to improve morbidity and mortality in systemic lupus erythematosus. Rheumatology (Oxford) 39(3):238–244CrossRef

22.

Salmon JE, Roman MJ (2001) Accelerated atherosclerosis in systemic lupus erythematosus: implications for patient management. Curr Opin Rheumatol 13(5):341–344PubMedCrossRef

23.

Noel B (2004) Risks and benefits of statins in lupus erythematosus. Arch Intern Med 164(1):107–108PubMedCrossRef

24.

Bruce IN (2005) Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin? Best Pract Res Clin Rheumatol 19(5):823–838PubMedCrossRef

25.

Petri M, Kiani AN, Post W et al (2006) Lupus atherosclerosis prevention study (LAPS): a randomized double blind placebo controlled trial of atorvastatin versus placebo (abstract). Arthritis Rheum 90S(54)

26.

Castelao AM, Grinyo JM, Castineiras MJ et al (1995) Effect of pravastatin in the treatment of hypercholesterolemia after renal transplantation under cyclosporine and prednisone. Transplant Proc 27(4):2217–2220PubMed

27.

Kobashigawa JA, Katznelson S, Laks H et al (1995) Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 333(10):621–627PubMedCrossRef

28.

Tan EM, Cohen AS, Fries JF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25(11):1271–1277PubMedCrossRef

29.

Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40(9):1725PubMedCrossRef

30.

Aizer J, Karlson EW, Chibnik LB et al (2006) A controlled comparison of brachial artery flow mediated dilation (FMD) and digital pulse amplitude tonometry (PAT) in the assessment of endothelial function in systemic lupus erythematosus (abstract). Arthritis Rheum (in press)

31.

Liang MH, Socher SA, Roberts WN et al (1988) Measurement of systemic lupus erythematosus activity in clinical research. Arthritis Rheum 31(7):817–825PubMedCrossRef

32.

Lennernas H, Fager G (1997) Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet 32(5):403–425PubMedCrossRef

33.

Knopp RH (1999) Drug treatment of lipid disorders. N Engl J Med 341(7):498–511PubMedCrossRef

34.

Maron DJ, Fazio S, Linton MF (2000) Current perspectives on statins. Circulation 101(2):207–213PubMed

35.

Vaughan CJ, Gotto AM Jr, Basson CT (2000) The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 35(1):1–10PubMedCrossRef

36.

Chong PH, Seeger JD, Franklin C (2001) Clinically relevant differences between the statins: implications for therapeutic selection. Am J Med 111(5):390–400PubMedCrossRef

37.

Shishov M, Koneru S, Houk JL et al (2005) The medication adherence self-report inventory (MASRI) can accurately measure adherence with medications in SLE (abstract). Arthritis Rheum 53:S424

38.

Kwak B, Mulhaupt F, Myit S et al (2000) Statins as a newly recognized type of immunomodulator. Nat Med 6(12):1399-1402PubMedCrossRef

39.

Kanda H, Hamasaki K, Kubo K et al (2002) Antiinflammatory effect of simvastatin in patients with rheumatoid arthritis. J Rheumatol 29(9):2024–2026PubMed

40.

McCarey DW, McInnes IB, Madhok R et al (2004) Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363(9426):2015–2021PubMedCrossRef

41.

Hedman M, Neuvonen PJ, Neuvonen M et al (2004) Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. Clin Pharmacol Ther 75(1):101–109PubMedCrossRef

42.

Butani L (2005) Prospective monitoring of lipid profiles in children receiving pravastatin preemptively after renal transplantation. Pediatr Transplant 9(6):746–753PubMedCrossRef

Title: A pravastatin dose-escalation study in systemic lupus erythematosus
Authors: Karen H. Costenbader
Matthew H. Liang
Lori B. Chibnik
Juliet Aizer
Hannah Kwon
Victoria Gall
Elizabeth W. Karlson
Publication date: 01-09-2007
Publisher: Springer-Verlag
Published in: Rheumatology International / Issue 11/2007
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-007-0341-6

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

A pravastatin dose-escalation study in systemic lupus erythematosus

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2007

The classification of fibromyalgia syndrome

Predicting factors for severity of rheumatoid arthritis: a prospective multicenter cohort study of 172 patients over 3 years

Activin A suppresses interleukin-1-induced matrix metalloproteinase 3 secretion in human chondrosarcoma cells

Is there a predisposition for the development of autoimmune diseases in patients with fibromyalgia? Retrospective analysis with long term follow-up

Transcription regulatory polymorphism −43T>C in the 5′-flanking region of SLC19A1 gene could affect rheumatoid arthritis patient response to methotrexate therapy

Protracted familial mediterranean fever arthritis presenting as septic arthritis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page